Immunotherapy: Immune-Related Adverse Events (irAEs) — Colitis, Pneumonitis, Endocrinopathy

Immunotherapy: Immune-Related Adverse Events (irAEs) — Colitis, Pneumonitis, Endocrinopathy

A practical guide for clinicians managing immunotherapy toxicities.

What Is This?

Immunotherapy (e.g., checkpoint inhibitors like PD-1/PD-L1 and CTLA-4 inhibitors) revolutionizes cancer treatment by unleashing the immune system against tumors. However, this immune activation can attack healthy tissues, causing immune-related adverse events (irAEs)—autoimmune-like toxicities affecting the colon (colitis), lungs (pneumonitis), and endocrine glands (endocrinopathy).

Why it matters today: - ~60% of patients on checkpoint inhibitors develop irAEs, with ~10–20% experiencing severe (grade 3–4) toxicity. - Early recognition and management prevent life-threatening complications (e.g., bowel perforation, respiratory failure, adrenal crisis). - Oncology, emergency medicine, and primary care teams must collaborate to balance cancer control with toxicity mitigation.

Why It Matters

Real-World Impact

1. Patient Survival vs. Toxicity Trade-off
2. Effective immunotherapy improves survival but irAEs can force treatment discontinuation (e.g., 30–50% of patients stop therapy due to colitis).

3. Mismanagement leads to hospitalization, ICU admission, or death (e.g., pneumonitis mortality ~5–10% if untreated).

4. Healthcare System Burden

5. irAEs increase ER visits, hospital stays, and steroid use, costing $10,000–$50,000 per patient in additional care.

6. Misdiagnosis (e.g., pneumonitis vs. infection) delays treatment and worsens outcomes.

7. Expanding Use of Immunotherapy

8. Approved for >20 cancer types (melanoma, lung, renal, bladder, etc.), with combination therapies (e.g., ipilimumab + nivolumab) increasing irAE risk.
9. Biomarkers (e.g., gut microbiome, PD-L1 status) are emerging to predict toxicity, but clinical vigilance remains critical.

Core Concepts

1. Mechanism of irAEs: "Friendly Fire"

• Checkpoint inhibitors block PD-1/PD-L1 or CTLA-4, removing "brakes" on T-cells.
• Result: T-cells attack both tumors and healthy tissues (e.g., colon epithelium, lung parenchyma, thyroid/pituitary glands).
• Key difference from chemotherapy toxicity:
• Delayed onset (weeks to months after treatment).
• Steroid-responsive (unlike chemo-induced damage).
• Recurrence risk with rechallenge.

2. irAE Grading (CTCAE v5.0)

3. Organ-Specific irAEs: The "Big Three"

4. Steroid Tapering: The Art of Withdrawal

• Start high, taper slow:
• Grade 2: Prednisone 0.5–1 mg/kg/day-taper over 4–6 weeks.
• Grade 3–4: Methylprednisolone 1–2 mg/kg IV-taper over 6–8 weeks.
• Risk of flare: If tapered too quickly, irAEs recur in ~30% of cases.
• Steroid-sparing agents:
• Colitis: Infliximab (anti-TNF-?).
• Pneumonitis: Mycophenolate mofetil (MMF).
• Endocrinopathy: Hormone replacement (no steroids needed).

5. Rechallenge: To Treat or Not to Treat?

• Low-grade irAEs (Grade 1–2): Can often restart immunotherapy after resolution.
• High-grade irAEs (Grade 3–4):
• Colitis/pneumonitis: Permanently discontinue (high recurrence risk).
• Endocrinopathy: May rechallenge if hormones are replaced (e.g., hypothyroidism).
• Decision factors:
• Cancer response (if CR/PR, consider alternative therapy).
• Patient preference (quality of life vs. survival benefit).

How It Works: The irAE Cascade

1. Immune Activation
2. Checkpoint inhibitor-T-cell expansion-cytokine release (IFN-?, TNF-?).
3. Tissue Infiltration
4. T-cells migrate to colon (CD8+), lungs (Th1/Th17), or endocrine glands (CD4+).
5. Inflammation & Damage
6. Colitis: Epithelial apoptosis-diarrhea, ulcers.
7. Pneumonitis: Alveolar damage-hypoxia.
8. Endocrinopathy: Gland destruction-hormone deficiency.
9. Clinical Manifestation
10. Symptoms appear weeks to months after treatment initiation.
11. Management
12. Steroids suppress T-cell activity.
13. Biologics (infliximab, MMF) block specific cytokines if steroids fail.

Hands-On: Step-by-Step irAE Management

Prerequisites

• Knowledge:
• Basic immunology (T-cell function, cytokine roles).
• CTCAE grading (Common Terminology Criteria for Adverse Events).
• Tools:
• Steroids (prednisone, methylprednisolone).
• Biologics (infliximab, mycophenolate).
• Diagnostic tests (CT, endoscopy, hormone panels).

Step 1: Recognize the irAE

Scenario: A patient on nivolumab (PD-1 inhibitor) for melanoma presents with new-onset diarrhea (6 stools/day) and abdominal pain.

Step 2: Initiate Treatment

1. Start prednisone 1 mg/kg/day (e.g., 60 mg daily for 70 kg patient).
2. Monitor for improvement (diarrhea should decrease in 2–3 days).
3. If no response in 3 days-escalate to infliximab 5 mg/kg IV.

Step 3: Taper Steroids

- After 1 week of symptom control:
  - Reduce prednisone by 10 mg every 5–7 days.
  - If symptoms recur-increase dose and slow taper.
- Total taper duration: 4–6 weeks.

Step 4: Rechallenge (If Applicable)

• If Grade 2 colitis resolves:
• Restart nivolumab with close monitoring (weekly clinic visits).
• Prophylaxis: Budesonide (9 mg/day) may reduce recurrence risk.

Common Pitfalls & Mistakes

1. Delaying Steroids

• Mistake: Waiting for "confirmatory" tests (e.g., colonoscopy) before starting steroids.
• Why it’s bad: Colitis can progress to perforation in 24–48 hours.
• Fix: Start steroids immediately if clinical suspicion is high (e.g., bloody diarrhea + CT findings).

2. Tapering Steroids Too Quickly

• Mistake: Reducing prednisone by >10 mg/week.
• Why it’s bad: 30% recurrence rate if tapered too fast.
• Fix: Follow a 4–6 week taper for Grade 2+ irAEs.

3. Misdiagnosing Pneumonitis as Infection

• Mistake: Treating dyspnea with antibiotics (e.g., for "pneumonia") without considering pneumonitis.
• Why it’s bad: Steroids are life-saving in pneumonitis; antibiotics delay treatment.
• Fix:
• CT chest (pneumonitis: diffuse ground-glass opacities; infection: lobar consolidation).
• Bronchoscopy if unclear (rule out PCP, CMV, fungal infection).

4. Ignoring Endocrinopathies

• Mistake: Attributing fatigue/hypotension to "cancer progression" or "depression."
• Why it’s bad: Adrenal crisis (hypophysitis) can be fatal if untreated.
• Fix:
• Check cortisol/ACTH in all patients with fatigue, headache, or hypotension.
• Start hydrocortisone 100 mg IV if adrenal insufficiency is suspected.

5. Rechallenging After Grade 3–4 irAEs

• Mistake: Restarting immunotherapy after severe colitis or pneumonitis.
• Why it’s bad: High recurrence risk (50–70%) with worse outcomes.
• Fix:
• Permanently discontinue for colitis/pneumonitis Grade 3–4.
• Consider alternative therapy (e.g., targeted therapy, chemotherapy).

Best Practices

1. Early Recognition: The "Red Flag" Symptoms

2. Multidisciplinary Approach

• Oncology: Manages immunotherapy and rechallenge decisions.
• Gastroenterology: Performs colonoscopy for colitis.
• Pulmonology: Evaluates pneumonitis (PFTs, bronchoscopy).
• Endocrinology: Manages hormone replacement for endocrinopathies.

3. Patient Education

• Teach patients to report symptoms early:
• "If you have new diarrhea, cough, or extreme fatigue, call us immediately."
• Provide a wallet card:
• "I am on immunotherapy. If I am hospitalized, do not give antibiotics for pneumonitis without consulting my oncologist."

4. Biomarkers & Risk Stratification

• High-risk patients:
• Combination immunotherapy (e.g., ipilimumab + nivolumab).
• History of autoimmune disease (e.g., IBD, lupus).
• Gut microbiome (e.g., Bacteroidetes associated with lower colitis risk).
• Emerging tools:
• Cytokine panels (e.g., IL-6, IFN-?) to predict irAEs.
• PD-L1 expression (higher in some studies = higher irAE risk).

5. Steroid-Sparing Strategies

• Colitis: Infliximab (5 mg/kg) if no response to steroids in 3–5 days.
• Pneumonitis: Mycophenolate mofetil (MMF) 1 g BID if refractory.
• Endocrinopathy: No steroids needed—replace hormones (e.g., levothyroxine, hydrocortisone).

Tools & Frameworks

Real-World Use Cases

1. Melanoma Patient with Colitis

• Scenario: 55-year-old male on ipilimumab + nivolumab for metastatic melanoma develops Grade 3 colitis (bloody diarrhea, fever).
• Management:
• Hold immunotherapy, start methylprednisolone 2 mg/kg IV.
• CT abdomen: Diffuse colitis.
• Colonoscopy: Severe ulcerations-infliximab 5 mg/kg.
• Outcome: Symptoms resolve in 5 days; permanently discontinue immunotherapy.

2. Lung Cancer Patient with Pneumonitis

• Scenario: 68-year-old female on pembrolizumab for NSCLC presents with dry cough and hypoxia (SpO2 88%).
• Management:
• CT chest: Diffuse ground-glass opacities.
• Bronchoscopy: Negative for infection.
• Diagnosis: Grade 3 pneumonitis.
• Treatment: Methylprednisolone 1 mg/kg IV-taper over 6 weeks.
• Outcome: Symptoms improve; pembrolizumab discontinued.

3. Renal Cell Carcinoma Patient with Hypophysitis

• Scenario: 45-year-old male on nivolumab develops fatigue, headache, and hypotension (BP 80/50).
• Management:
• Labs: Low cortisol (<3 mcg/dL), low ACTH, low testosterone.
• MRI brain: Enlarged pituitary gland.
• Diagnosis: Grade 2 hypophysitis.
• Treatment: Hydrocortisone 20 mg AM/10 mg PM + levothyroxine.
• Outcome: Symptoms resolve; nivolumab restarted with monitoring.

Check Your Understanding (MCQs)

Question 1

A 62-year-old woman with metastatic melanoma on ipilimumab + nivolumab presents with 5–6 loose stools/day and mild abdominal cramping. Stool studies are negative for infection. CT abdomen shows mild colonic wall thickening. What is the next best step?

A. Start loperamide and continue immunotherapy. B. Start prednisone 1 mg/kg/day and hold immunotherapy. C. Order a colonoscopy before starting steroids. D. Start infliximab 5 mg/kg immediately.